drugset / Trial / NCT02173730

BIBR 953 ZW in Healthy Elderly Subjects

NCT02173730

Phase 1 Completed 36 enrolled Boehringer Ingelheim
RandomizedParallel-groupOpen-labelTreatment

Summary

To assess the steady state pharmacokinetic profile of BIBR 953 ZW after administration of BIBR 1048 to male and female elderly subjects, to assess pharmacokinetic gender differences. To assess the effect of coadministration of Pantoprazole on the bioavailability of BIBR 953 ZW.

Timeline

Start
2002-11
Primary completion
2003-02
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Dabigatran etexilate Unknown 150 mg Oral
Subject Pantoprazole Other / unclassified 40 mg Oral

Indications

No indication recorded.